Add this topic to your myFT Digest for news straight to your inbox
Companies sell off businesses to focus on speciality areas such as Covid vaccine ingredients
Swiss group needs to reinvest proceeds from unit sale into more promising areas of growth
Deal will boost Swiss group’s boost healthcare operations and provide control over drug production
The Alpine nation is battling to curb a rise in its currency, writes Haig Simonian
The deal is less than pristine, in the market’s view
International Edition